# TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

> **NCT05434312** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shenzhen TargetRx Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** TGRX-678

## Key facts

- **NCT ID:** NCT05434312
- **Lead sponsor:** Shenzhen TargetRx Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-29
- **Primary completion:** 2026-03
- **Final completion:** 2026-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05434312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05434312, "TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05434312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*